Second-Line Therapy in Pancreatic Cancer

  • Evangelia Skoura Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital; Nuclear Medicine Department, Evangelismos General Hospital. Athens, Greece
  • Konstantinos N Syrigos Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital. Athens, Greece
  • Muhammad Wasif Saif Tufts University School of Medicine. Boston, MA, USA
Keywords: 5-fluoropyrimidine, Drug Therapy, Combination, irinotecan, Pancreatic Neoplasms, S 1 (combination)


At the time of diagnosis most of patients present with advanced or metastatic pancreatic cancer, thereby precluding surgical resection. While the standard of care in the first line setting is established, there are limited data to support a standard second-line chemotherapy regimen. The authors summarize two interesting studies (Abstract #263 and Abstract #287) presented at the 2013 ASCO Gastrointestinal Cancers Symposium. These studies concern two phase II trials about second-line chemotherapy in pancreatic cancer. The first one evaluated the role of fluoropyrimidine as monotherapy versus fluoropyrimidine in combination with irinotecan (Abstract #263) and the second one compared the fluoropyrimidine treatment with the continuation of gemcitabine as monotherapy (Abstract #287).

Image: Oncology Unit, Sotiria General Hospital. Athens, Greece.


Download data is not yet available.


Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics. CA Cancer J Clin. 2008; 58: 71-96.

Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, et al. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol. 2012; 18:1357-64.

Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011; 47: 1676-81.

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008; 113: 2046-52.

Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol. 2002;20:3130-6.

Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 4508).

Mizuno N, Yamao K, Komatsu Y, Munakata M, Ishiguro A, Yamaguchi T, et al. Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer. J Clin Oncol 30: 2012 (suppl 34; abstr 263).

Ioka T, Katayama K, Ishida N, Takada R, Yamai T, Fukutake N, et al. Randomized phase II study of best avilabe fluoro pyrimidine compared with continuation of gemcitabine (Gem) monotherapy in patients with Gem-refractory pancreatic cancer. J Clin Oncol 30: 2012 (suppl 34; abstr 287).

Gounaris I, Zaki K, Corrie P. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer. JOP. 2010; 11: 113-23.

Oncology Unit, Sotiria General Hospital. Athens, Greece
How to Cite
SkouraE., SyrigosK., & SaifM. (2013). Second-Line Therapy in Pancreatic Cancer. JOP. Journal of the Pancreas, 14(2), 133-134.
Highlights from the “2013 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 24-26, 2013

Most read articles by the same author(s)

1 2 3 > >>